{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:25Z","timestamp":1786982125861,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>To integrate clinical and preclinical evidence on insulin-like growth factor-binding protein-7 (IGFBP7) in heart failure (HF) and identify key priorities for advancing IGFBP7-targeted therapies toward human translation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Circulating IGFBP7 is strongly associated with HF development, diastolic dysfunction, and disease progression across HF phenotypes. Preclinical studies show that genetic or pharmacologic inhibition of IGFBP7 attenuates cardiac remodelling, reduces cardiomyocyte senescence, and ameliorates cardiac dysfunction in murine HF models. Apparent mechanistic discrepancies between studies likely reflect cell-specific actions: cardiomyocyte-derived IGFBP7 activates IGF-1 receptor signalling, promoting cardiomyocyte hypertrophy and senescence, whereas endothelial-derived IGFBP7 inhibits cardiomyocyte insulin receptor signalling, impairing metabolic homeostasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>IGFBP7 is a senescence-associated biomarker linked to HF development, diastolic dysfunction, and HF progression. Preclinical studies converge on the conclusion that IGFBP7 inhibition attenuates cardiac remodelling and ameliorates cardiac dysfunction in experimental HF, positioning IGFBP7 as a promising therapeutic target. Ongoing research into IGFBP7-targeted strategies may expand HF treatment beyond conventional hemodynamic and neurohormonal interventions by directly addressing the biology of cardiovascular ageing and senescence-driven myocardial dysfunction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11897-026-00750-3","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T06:29:09Z","timestamp":1776752949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["IGFBP7 and Heart Failure: From Senescence Biomarker to Therapeutic Target"],"prefix":"10.1007","volume":"23","author":[{"given":"Maissa","family":"El-Qendouci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Chelu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Abdellatif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep","family":"Jhund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4775-9140","authenticated-orcid":false,"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7781-2897","authenticated-orcid":false,"given":"Navin","family":"Suthahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"750_CR1","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nrcardio.2016.25","volume":"13","author":"B Ziaeian","year":"2016","unstructured":"Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13:368\u201378.","journal-title":"Nat Rev Cardiol"},{"key":"750_CR2","doi-asserted-by":"publisher","first-page":"l223","DOI":"10.1136\/bmj.l223","volume":"364","author":"CJ Taylor","year":"2019","unstructured":"Taylor CJ, Ord\u00f3\u00f1ez-Mena JM, Roalfe AK, Lay-Flurrie S, Jones NR, Marshall T, et al. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000\u20132017: population based cohort study. BMJ. 2019;364:l223.","journal-title":"BMJ"},{"key":"750_CR3","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.15420\/cfr.2023.05","volume":"9","author":"B Shahim","year":"2023","unstructured":"Shahim B, Kapelios CJ, Savarese G, Lund LH. Global Public Health Burden of Heart Failure: An Updated Review. Card Fail Rev. 2023;9:e11.","journal-title":"Card Fail Rev"},{"key":"750_CR4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10741-019-09860-8","volume":"25","author":"L Grosman-Rimon","year":"2020","unstructured":"Grosman-Rimon L, Billia F, Wright E, Carasso S, Elbaz-Greener G, Kachel E, et al. Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure. Heart Fail Rev. 2020;25:685\u2013701.","journal-title":"Heart Fail Rev"},{"key":"750_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11897-017-0343-y","volume":"14","author":"N Suthahar","year":"2017","unstructured":"Suthahar N, Meijers WC, Sillj\u00e9 HHW, Boer RA. de. From inflammation to fibrosis\u2014molecular and cellular mechanisms of myocardial tissue remodelling and perspectives on differential treatment opportunities. Curr Heart Fail Rep. 2017;14:235\u201350.","journal-title":"Curr Heart Fail Rep"},{"key":"750_CR6","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/s41569-023-00881-3","volume":"20","author":"M Abdellatif","year":"2023","unstructured":"Abdellatif M, Rainer PP, Sedej S, Kroemer G. Hallmarks of cardiovascular ageing. Nat Rev Cardiol. 2023;20:754\u201377.","journal-title":"Nat Rev Cardiol"},{"key":"750_CR7","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41569-021-00624-2","volume":"19","author":"M Mehdizadeh","year":"2022","unstructured":"Mehdizadeh M, Aguilar M, Thorin E, Ferbeyre G, Nattel S. The role of cellular senescence in cardiac disease: basic biology and clinical relevance. Nat Rev Cardiol. 2022;19:250\u201364.","journal-title":"Nat Rev Cardiol"},{"key":"750_CR8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jchf.2024.02.021","volume":"12","author":"P Goyal","year":"2024","unstructured":"Goyal P, Maurer MS, Roh J. Aging in Heart Failure: Embracing Biology Over Chronology: JACC Family Series. JACC Heart Fail. 2024;12:795\u2013809.","journal-title":"JACC Heart Fail"},{"key":"750_CR9","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1093\/cvr\/cvae177","volume":"121","author":"M Abdellatif","year":"2025","unstructured":"Abdellatif M, Schmid ST, Fuerlinger A, Kroemer G. Anti-ageing interventions for the treatment of cardiovascular disease. Cardiovasc Res. 2025;121:1524\u201336.","journal-title":"Cardiovasc Res"},{"key":"750_CR10","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/febs.16351","volume":"290","author":"M Sweeney","year":"2023","unstructured":"Sweeney M, Cook SA, Gil J. Therapeutic opportunities for senolysis in cardiovascular disease. FEBS J. 2023;290:1235\u201355.","journal-title":"FEBS J"},{"key":"750_CR11","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1161\/CIRCULATIONAHA.122.059863","volume":"145","author":"M Abdellatif","year":"2022","unstructured":"Abdellatif M, Trummer-Herbst V, Heberle AM, Humnig A, Pendl T, Durand S, et al. Fine-Tuning Cardiac Insulin-Like Growth Factor 1 Receptor Signaling to Promote Health and Longevity. Circulation. 2022;145:1853\u201366.","journal-title":"Circulation"},{"key":"750_CR12","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1093\/eurjhf\/hfq166","volume":"12","author":"S Watanabe","year":"2010","unstructured":"Watanabe S, Tamura T, Ono K, Horiuchi H, Kimura T, Kita T, et al. Insulin-like growth factor axis (insulin-like growth factor-I\/insulin-like growth factor-binding protein-3) as a prognostic predictor of heart failure: association with adiponectin. Eur J Heart Fail. 2010;12:1214\u201322.","journal-title":"Eur J Heart Fail"},{"key":"750_CR13","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nrendo.2013.67","volume":"9","author":"RK Junnila","year":"2013","unstructured":"Junnila RK, List EO, Berryman DE, Murrey JW, Kopchick JJ. The GH\/IGF-1 axis in ageing and longevity. Nat Rev Endocrinol. 2013;9:366\u201376.","journal-title":"Nat Rev Endocrinol"},{"key":"750_CR14","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1002\/pmic.201200455","volume":"13","author":"S Chugh","year":"2013","unstructured":"Chugh S, Ouzounian M, Lu Z, Mohamed S, Li W, Bousette N, et al. Pilot study identifying myosin heavy chain 7, desmin, insulin-like growth factor 7, and annexin A2 as circulating biomarkers of human heart failure. Proteomics. 2013;13:2324\u201334.","journal-title":"Proteomics"},{"key":"750_CR15","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/ejhf.3328","volume":"27","author":"S Abou Kamar","year":"2025","unstructured":"Abou Kamar S, Bracun V, El-Qendouci M, Bomer N, Bakker SJL, Gansevoort RT, et al. Association of baseline and longitudinal changes in insulin-like growth factor-binding protein-7 with the risk of incident heart failure: Data from the PREVEND study. Eur J Heart Fail. 2025;27:1755\u201363.","journal-title":"Eur J Heart Fail"},{"key":"750_CR16","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1002\/ehf2.14120","volume":"9","author":"V Bracun","year":"2022","unstructured":"Bracun V, van Essen B, Voors AA, van Veldhuisen DJ, Dickstein K, Zannad F, et al. Insulin-like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence. ESC Heart Fail. 2022;9:4167\u201376.","journal-title":"ESC Heart Fail"},{"key":"750_CR17","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/ejhf.3227","volume":"26","author":"JP Ferreira","year":"2024","unstructured":"Ferreira JP, Packer M, Sattar N, Butler J, Gonz\u00e1lez Maldonado S, Panova-Noeva M, et al. Insulin-like growth factor binding protein-7 concentrations in chronic heart failure: Results from the EMPEROR programme. Eur J Heart Fail. 2024;26:806\u201316.","journal-title":"Eur J Heart Fail"},{"key":"750_CR18","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s44161-022-00181-y","volume":"1","author":"L Zhang","year":"2022","unstructured":"Zhang L, Smyth D, Al-Khalaf M, Blet A, Du Q, Bernick J, et al. Insulin-like growth factor-binding protein-7 (IGFBP7) links senescence to heart failure. Nat Cardiovasc Res. 2022;1:1195\u2013214.","journal-title":"Nat Cardiovasc Res"},{"key":"750_CR19","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1161\/CIRCULATIONAHA.123.064719","volume":"150","author":"M Katoh","year":"2024","unstructured":"Katoh M, Nomura S, Yamada S, Ito M, Hayashi H, Katagiri M, et al. Vaccine Therapy for Heart Failure Targeting the Inflammatory Cytokine Igfbp7. Circulation. 2024;150:374\u201389.","journal-title":"Circulation"},{"key":"750_CR20","unstructured":"Tissue expression of IGFBP7 - Summary. - The human protein atlas available from: https:\/\/www.proteinatlas.org\/ENSG00000163453-IGFBP7\/tissue. Accessed 18 Feb 2026."},{"key":"750_CR21","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1186\/cc12503","volume":"17","author":"K Kashani","year":"2013","unstructured":"Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013;17:R25.","journal-title":"Crit Care"},{"key":"750_CR22","first-page":"2054","volume":"29","author":"EAJ Hoste","year":"2014","unstructured":"Hoste EAJ, McCullough PA, Kashani K, Chawla LS, Joannidis M, Shaw AD, et al. Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers. Nephrol Dial Transpl Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2014;29:2054\u201361.","journal-title":"Nephrol Dial Transpl Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"750_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2147\/IJNRD.S198222","volume":"13","author":"F Nalesso","year":"2020","unstructured":"Nalesso F, Cattarin L, Gobbi L, Fragasso A, Garzotto F, Cal\u00f2 LA. Evaluating Nephrocheck\u00ae as a Predictive Tool for Acute Kidney Injury. Int J Nephrol Renov Dis. 2020;13:85\u201396.","journal-title":"Int J Nephrol Renov Dis"},{"key":"750_CR24","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41598-020-80196-2","volume":"11","author":"K Esmeijer","year":"2021","unstructured":"Esmeijer K, Schoe A, Ruhaak LR, Hoogeveen EK, Soonawala D, Romijn FPHTM, et al. The predictive value of TIMP-2 and IGFBP7 for kidney failure and 30-day mortality after elective cardiac surgery. Sci Rep. 2021;11:1071.","journal-title":"Sci Rep"},{"key":"750_CR25","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.3390\/jcm13082220","volume":"13","author":"A Szyszkowska","year":"2024","unstructured":"Szyszkowska A, Olesiewicz T, P\u0142o\u0144ska-Korabiewska I, Tarasiuk E, Olesiewicz B, Knapp M, et al. The Importance of Lung Ultrasound and IGFBP7 (Insulin-like Growth Factor Binding Protein 7) Assessment in Diagnosing Patients with Heart Failure. J Clin Med. 2024;13:2220.","journal-title":"J Clin Med"},{"key":"750_CR26","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1002\/ehf2.14335","volume":"10","author":"P Puar","year":"2023","unstructured":"Puar P, Mistry N, Connelly KA, Yan AT, Quan A, Teoh H, et al. IGFBP7 and left ventricular mass regression: a sub-analysis of the EMPA-HEART CardioLink-6 randomized clinical trial. ESC Heart Fail. 2023;10:2113\u20139.","journal-title":"ESC Heart Fail"},{"key":"750_CR27","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/j.amjcard.2018.02.041","volume":"121","author":"C Hage","year":"2018","unstructured":"Hage C, Bjerre M, Frystyk J, Gu HF, Brismar K, Donal E, et al. Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction. Am J Cardiol. 2018;121:1558\u201366.","journal-title":"Am J Cardiol"},{"key":"750_CR28","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.120.045810","volume":"142","author":"S Sanders-van Wijk","year":"2020","unstructured":"Sanders-van Wijk S, Tromp J, Beussink-Nelson L, Hage C, Svedlund S, Saraste A, et al. Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction: Results From the PROMIS-HFpEF Study. Circulation. 2020;142:2029\u201344.","journal-title":"Circulation"},{"key":"750_CR29","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1210\/jc.2018-01241","volume":"103","author":"M Brankovic","year":"2018","unstructured":"Brankovic M, Akkerhuis KM, Mouthaan H, Brugts JJ, Manintveld OC, van Ramshorst J, et al. Cardiometabolic Biomarkers and Their Temporal Patterns Predict Poor Outcome in Chronic Heart Failure (Bio-SHiFT Study). J Clin Endocrinol Metab. 2018;103:3954\u201364.","journal-title":"J Clin Endocrinol Metab"},{"key":"750_CR30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2337\/dc20-1889","volume":"44","author":"JL Januzzi","year":"2021","unstructured":"Januzzi JL, Butler J, Sattar N, Xu J, Shaw W, Rosenthal N, et al. Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study. Diabetes Care. 2021;44:210\u20136.","journal-title":"Diabetes Care"},{"key":"750_CR31","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jchf.2016.08.002","volume":"4","author":"PU Gandhi","year":"2016","unstructured":"Gandhi PU, Gaggin HK, Redfield MM, Chen HH, Stevens SR, Anstrom KJ, et al. Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial. JACC Heart Fail. 2016;4:860\u20139.","journal-title":"JACC Heart Fail"},{"key":"750_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cardfail.2016.06.006","volume":"23","author":"PU Gandhi","year":"2017","unstructured":"Gandhi PU, Chow SL, Rector TS, Krum H, Gaggin HK, McMurray JJ, et al. Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. J Card Fail. 2017;23:20\u20138.","journal-title":"J Card Fail"},{"key":"750_CR33","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jchf.2023.01.016","volume":"11","author":"ESJ Tan","year":"2023","unstructured":"Tan ESJ, Chan S-P, Choi YC, Pemberton CJ, Troughton R, Poppe K, et al. Regional Handling and Prognostic Performance of Circulating Insulin-Like Growth Factor Binding Protein-7 in Heart Failure. JACC Heart Fail. 2023;11:662\u201374.","journal-title":"JACC Heart Fail"},{"key":"750_CR34","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.hrthm.2020.11.028","volume":"18","author":"S Blum","year":"2021","unstructured":"Blum S, Aeschbacher S, Meyre P, K\u00fchne M, Rodondi N, Beer JH, et al. Insulin-like growth factor-binding protein 7 and risk of congestive heart failure hospitalization in patients with atrial fibrillation. Heart Rhythm. 2021;18:512\u20139.","journal-title":"Heart Rhythm"},{"key":"750_CR35","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/ehf2.12722","volume":"7","author":"A Kalayci","year":"2020","unstructured":"Kalayci A, Peacock WF, Nagurney JT, Hollander JE, Levy PD, Singer AJ, et al. Echocardiographic assessment of insulin-like growth factor binding protein-7 and early identification of acute heart failure. ESC Heart Fail. 2020;7:1664\u201375.","journal-title":"ESC Heart Fail"},{"key":"750_CR36","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.amjcard.2014.08.018","volume":"114","author":"PU Gandhi","year":"2014","unstructured":"Gandhi PU, Gaggin HK, Sheftel AD, Belcher AM, Weiner RB, Baggish AL, et al. Prognostic usefulness of insulin-like growth factor-binding protein 7 in heart failure with reduced ejection fraction: a novel biomarker of myocardial diastolic function? Am J Cardiol. 2014;114:1543\u20139.","journal-title":"Am J Cardiol"},{"key":"750_CR37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12872-016-0376-2","volume":"16","author":"MC Barroso","year":"2016","unstructured":"Barroso MC, Kramer F, Greene SJ, Scheyer D, K\u00f6hler T, Karoff M, et al. Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction. BMC Cardiovasc Disord. 2016;16:199.","journal-title":"BMC Cardiovasc Disord"},{"key":"750_CR38","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jchf.2022.09.004","volume":"11","author":"C Adamson","year":"2023","unstructured":"Adamson C, Welsh P, Docherty KF, de Boer RA, Diez M, Dro\u017cd\u017c J, et al. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF. JACC Heart Fail. 2023;11:291\u2013304.","journal-title":"JACC Heart Fail"},{"key":"750_CR39","doi-asserted-by":"crossref","unstructured":"Shah AM, Myhre PL, Arthur V, Dorbala P, Rasheed H, Buckley LF et al. Large scale plasma proteomics identifies novel proteins and protein networks associated with heart failure development. Nat Commun 2024;15:528.","DOI":"10.1038\/s41467-023-44680-3"},{"key":"750_CR40","doi-asserted-by":"publisher","first-page":"eaag1166","DOI":"10.1126\/scitranslmed.aag1166","volume":"9","author":"C Finan","year":"2017","unstructured":"Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, et al. The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017;9:eaag1166.","journal-title":"Sci Transl Med"},{"key":"750_CR41","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41574-025-01120-0","volume":"21","author":"N Suthahar","year":"2025","unstructured":"Suthahar N, Bergman RN, de Boer RA. Replacing body mass index with relative fat mass to accurately estimate adiposity. Nat Rev Endocrinol. 2025;21:393\u20134.","journal-title":"Nat Rev Endocrinol"},{"key":"750_CR42","doi-asserted-by":"publisher","first-page":"e005133","DOI":"10.1161\/CIRCHEARTFAILURE.118.005133","volume":"11","author":"JL Januzzi","year":"2018","unstructured":"Januzzi JL, Packer M, Claggett B, Liu J, Shah AM, Zile MR, et al. IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure. Circ Heart Fail. 2018;11:e005133.","journal-title":"Circ Heart Fail"},{"key":"750_CR43","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s12265-013-9522-8","volume":"7","author":"SR Motiwala","year":"2014","unstructured":"Motiwala SR, Szymonifka J, Belcher A, Weiner RB, Baggish AL, Gaggin HK, et al. Measurement of novel biomarkers to predict chronic heart failure outcomes and left ventricular remodeling. J Cardiovasc Transl Res. 2014;7:250\u201361.","journal-title":"J Cardiovasc Transl Res"},{"key":"750_CR44","doi-asserted-by":"publisher","first-page":"100734","DOI":"10.1016\/j.lanhl.2025.100734","volume":"6","author":"NR Jones","year":"2025","unstructured":"Jones NR, Smith M, Yang Y, Hobbs FDR, Taylor CJ. Trends in mortality in people with heart failure and atrial fibrillation: a population-based cohort study. Lancet Healthy Longev. 2025;6:100734.","journal-title":"Lancet Healthy Longev"},{"key":"750_CR45","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s44325-025-00079-1","volume":"2","author":"N Suthahar","year":"2025","unstructured":"Suthahar N, Gansevoort RT, Kok TF, El-Qendouci M, Petersen TB, Bakker SJL, et al. The senescence-inducing factor IGFBP7 and risk of atrial fibrillation: findings from the PREVEND study. NPJ Cardiovasc Health. 2025;2:42.","journal-title":"NPJ Cardiovasc Health"},{"key":"750_CR46","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1161\/CIRCULATIONAHA.124.067059","volume":"150","author":"JP Aboumsallem","year":"2024","unstructured":"Aboumsallem JP. RA de <>Boer 2024 IGFBP7: From Senescence Biomarker to a Vaccine for Heart Failure. Circulation 150 390\u20132.","journal-title":"Circulation"},{"key":"750_CR47","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.devcel.2014.11.012","volume":"31","author":"M Demaria","year":"2014","unstructured":"Demaria M, Ohtani N, Youssef SA, Rodier F, Toussaint W, Mitchell JR, et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev Cell. 2014;31:722\u201333.","journal-title":"Dev Cell"},{"key":"750_CR48","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","volume":"22","author":"L Wang","year":"2022","unstructured":"Wang L, Lankhorst L, Bernards R. Exploiting senescence for the treatment of cancer. Nat Rev Cancer. 2022;22:340\u201355.","journal-title":"Nat Rev Cancer"},{"key":"750_CR49","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.ccell.2025.05.015","volume":"43","author":"M Colucci","year":"2025","unstructured":"Colucci M, Sarill M, Maddalena M, Valdata A, Troiani M, Massarotti M, et al. Senescence in cancer. Cancer Cell. 2025;43:1204\u201326.","journal-title":"Cancer Cell"},{"key":"750_CR50","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3389\/fonc.2020.00727","volume":"10","author":"L Jin","year":"2020","unstructured":"Jin L, Shen F, Weinfeld M, Sergi C. Insulin Growth Factor Binding Protein 7 (IGFBP7)-Related Cancer and IGFBP3 and IGFBP7 Crosstalk. Front Oncol. 2020;10:727.","journal-title":"Front Oncol"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-026-00750-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-026-00750-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-026-00750-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:27:59Z","timestamp":1781648879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-026-00750-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["750"],"URL":"https:\/\/doi.org\/10.1007\/s11897-026-00750-3","relation":{},"ISSN":["1546-9549"],"issn-type":[{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Competing interests: Drs. Suthahar and de Boer are inventors on a published patent (WO2025061752) related to Bone Morphogenetic Protein-10 (BMP10), titled \u201cCirculating BMP10 in the Assessment of Congestion and Pulmonary Hypertension.\u201d Dr. de Boer has had speaker engagements with and\/or received fees from and\/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll. R.A.d.B. received travel support from Abbott and NovoNordisk. The institution where Dr. de Boer is employed has received research grants and\/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk and Roche. The remaining authors do not have anything to disclose. Acknowledgements: Drs. de Boer and Suthahar are supported by the Netherlands Heart Foundation (Nederlandse Hartstichting) through grants 2020B005 (DOUBLE DOSE) and 01-003-2022-0358 (CARMA), by the Netherlands Organization for Scientific Research (Nederlandse Organisatie voor Wetenschappelijk Onderzoek), co-funded by ERA4Health through the CARDINNOV 2023 call, as part of the EnerLIGHT project (Grant Agreement N. 101095426 of the EU Horizon Europe Research and Innovation Programme) and by the European Research Council (ERC CoG 818715; SECRETE-HF).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}